Latest Decheng Capital LLC Stock Portfolio
Decheng Capital LLC Performance:
2025 Q4: 36.33%YTD: 68.98%2024: -8.09%
Performance for 2025 Q4 is 36.33%, and YTD is 68.98%, and 2024 is -8.09%.
About Decheng Capital LLC and 13F Hedge Fund Stock Holdings
On 2026-02-12, the fund reported it's updated stock portfolio. In the 13F Holdings report, Decheng Capital LLC reported an equity portfolio of $743.4 Millions as of 31 Dec, 2025.
The top stock holdings of Decheng Capital LLC are , NUVB, . The fund has invested 35.6% of it's portfolio in CG ONCOLOGY INC and 31.3% of portfolio in NUVATION BIO INC.
The fund managers got completely rid off MERUS NV (MRUS), MOONLAKE IMMUNOTHERAPEUTICS and ILLUMNIA, INC. (ILMN) stocks. They significantly reduced their stock positions in 4D MOLECULAR THERAPEUTICS IN (FDMT), KRYSTAL BIOTECH INC (KRYS) and CRINETICS PHARMACEUTICALS IN (CRNX). The fund showed a lot of confidence in some stocks as they added substantially to LYELL IMMUNOPHARMA, INC. (LYEL).
The top stock holdings of Decheng Capital LLC are , NUVB, . The fund has invested 35.6% of it's portfolio in CG ONCOLOGY INC and 31.3% of portfolio in NUVATION BIO INC.
The fund managers got completely rid off MERUS NV (MRUS), MOONLAKE IMMUNOTHERAPEUTICS and ILLUMNIA, INC. (ILMN) stocks. They significantly reduced their stock positions in 4D MOLECULAR THERAPEUTICS IN (FDMT), KRYSTAL BIOTECH INC (KRYS) and CRINETICS PHARMACEUTICALS IN (CRNX). The fund showed a lot of confidence in some stocks as they added substantially to LYELL IMMUNOPHARMA, INC. (LYEL).
Decheng Capital LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Decheng Capital LLC made a return of 36.33% in the last quarter. In trailing 12 months, it's portfolio return was 68.98%.
- Performance
- S&P 500
New Buys
Additions
| Ticker | % Inc. |
|---|---|
| lyell immunopharma, inc. | 16.22 |
Additions to existing portfolio by Decheng Capital LLC
Reductions
| Ticker | % Reduced |
|---|---|
| 4d molecular therapeutics in | -52.22 |
| krystal biotech inc | -46.44 |
| crinetics pharmaceuticals in | -35.17 |
| aura biosciences, inc. | -30.08 |
| beyondspring inc. | -11.33 |
| newamsterdam pharma co nv | -9.89 |
| revolution medicines inc(nsm) | -4.76 |
| upstream bio inc. | -4.33 |
Decheng Capital LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| merus nv | -17,563,300 |
| moonlake immunotherapeutics | -1,302,070 |
| grail inc | -572,615 |
| illumnia, inc. | -757,766 |
Decheng Capital LLC got rid off the above stocks
Sector Distribution
Decheng Capital LLC has about 57.6% of it's holdings in Others sector.
- Others
- Healthcare
| Sector | % |
|---|---|
| Others | 57.6 |
| Healthcare | 42.4 |
Market Cap. Distribution
Decheng Capital LLC has about 2.1% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- SMALL-CAP
- MID-CAP
- LARGE-CAP
- MICRO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 57.6 |
| SMALL-CAP | 36.1 |
| MID-CAP | 2.9 |
| LARGE-CAP | 2.1 |
| MICRO-CAP | 1.2 |
Stocks belong to which Index?
About 41.4% of the stocks held by Decheng Capital LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 58.6 |
| RUSSELL 2000 | 41.4 |
Decheng Capital LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Decheng Capital LLC
Decheng Capital LLC has 19 stocks in it's portfolio. About 97.4% of the portfolio is in top 10 stocks. BYSI proved to be the most loss making stock for the portfolio. NUVB was the most profitable stock for Decheng Capital LLC last quarter.
Last Reported on: 12 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACRS | aclaris therapeutics, inc. | 1.64 | 4,041,740 | 12,165,600 | unchanged | 0.00 | ||
| AURA | aura biosciences, inc. | 0.26 | 360,483 | 1,964,630 | reduced | -30.08 | ||
| BYSI | beyondspring inc. | 0.83 | 3,800,700 | 6,195,140 | reduced | -11.33 | ||
| CRNX | crinetics pharmaceuticals in | 0.58 | 92,700 | 4,315,180 | reduced | -35.17 | ||
| EQ | equillium inc. | 0.93 | 4,447,310 | 6,893,330 | unchanged | 0.00 | ||
| FDMT | 4d molecular therapeutics in | 0.04 | 44,311 | 332,333 | reduced | -52.22 | ||
| ILMN | illumnia, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| KRYS | krystal biotech inc | 0.57 | 17,300 | 4,265,140 | reduced | -46.44 | ||
| LYEL | lyell immunopharma, inc. | 2.87 | 692,050 | 21,301,300 | added | 16.22 | ||
| MRUS | merus nv | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| NAMS | newamsterdam pharma co nv | 2.79 | 592,057 | 20,769,400 | reduced | -9.89 | ||
| NUVB | nuvation bio inc. | 31.28 | 25,954,400 | 232,552,000 | unchanged | 0.00 | ||
| NUVB | nuvation bio inc. | 0.03 | 646,057 | 213,198 | unchanged | 0.00 | ||
| PYXS | pyxis oncology, inc (formerly apexigen) | 0.05 | 326,810 | 375,832 | unchanged | 0.00 | ||
| RCUS | arcus biosciences, inc | 1.74 | 541,559 | 12,905,400 | reduced | -1.1 | ||
| RVMD | revolution medicines inc(nsm) | 2.14 | 200,000 | 15,930,000 | reduced | -4.76 | ||
| RZLT | rezolute inc | 0.02 | 59,900 | 141,364 | unchanged | 0.00 | ||
| ZNTL | zentalis pharmaceuticals inc. | 0.24 | 1,323,330 | 1,786,490 | unchanged | 0.00 | ||
| cg oncology inc | 35.59 | 6,371,670 | 264,552,000 | unchanged | 0.00 | |||
| upstream bio inc. | 11.48 | 3,143,080 | 85,334,600 | reduced | -4.33 | |||